benzbromarone

Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase used primarily for the treatment and prevention of gout, especially in patients who are intolerant to or do not respond to first-line therapies like allopurinol. It lowers plasma uric acid concentrations by blocking renal tubular reabsorption of uric acid, mainly through inhibition of the urate transporter 1 (URAT1) in the proximal renal tubule, and possibly by increasing intestinal elimination of uric acid. Benzbromarone is structurally related to amiodarone and has also been shown to be a potent inhibitor of cytochrome P450 enzymes CYP2C9 and CYP2C19. The drug was introduced in the 1970s, marketed widely outside the United States, but withdrawn by Sanofi-Synthélabo in 2003 due to reports of serious hepatotoxicity; it remains available from other manufacturers in some countries. Clinical trials have suggested it may be more effective than both allopurinol and probenecid for lowering serum uric acid levels[1][3][4][5][6].

Brand names

BenzbromaroneBenzbromaron ALBenzbromarone TevaBenaroneBenroneBemaronBeenroneBenzmaronBenzon

Other names

2-ethyl-3-(3,5-dibromo-4-hydroxybenzoyl)benzofuran3,5-dibromo-4-hydroxyphenyl-(2‑ethyl‑3‑benzofuranyl) ketonebenzbromaronabenzbromaronum